Navigation Links

LOS ANGELES, Sept. 25, 2013 /PRNewswire-iReach/ -- Applied Integrin Sciences, Inc. announced today it launched its first crowdfunding campaign to raise funding to accelerate the development of its cancer-fighting drug that is planned to boost the survival and quality of life for patients with ovarian cancer, breast cancer, prostate cancer, and other cancers, an initiative facilitated by the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California; Three Two One Productions; When You Wish; and the women who share their ovarian cancer experiences: Diem Brown, Entertainment reporter and former contestant on MTV's Real World/Road Rules Challenge, who shares her experience of being diagnosed with ovarian cancer at age 23 (The MEDGift Foundation);  Amy Cohen Epstein who watched her mother, Lynne Cohen, suffer and succumb from ovarian cancer (Lynne Cohen Foundation); Paulinda Schimmel Babbini who saw her daughter, Robin, diagnosed with ovarian cancer at age 17 and  lose her life at age 20 (The Ovarian Cancer Circle); and, Diane Balma, former executive at the Susan G. Komen For the Cure, explains the importance of involving the general public in supporting medical research for cancer.

Through the miracle of the internet and social media the public now has the opportunity to directly fund cutting-edge cancer research and drug development.  To donate to the company's drug development program simply click on the following WhenYouWish link:  

1 minute of your time and a donation of your choosing will make a difference.

Applied Integrin Sciences, Inc. scientists' at the University of Southern California Keck School of Medicine and the USC Norris Comprehensive Cancer Center discovered a novel cancer-fighting therapeutic drug has demonstrated effective reduction of tumor growth and progression on six aggressive tumors: triple negative breast cancer, ovarian cancer, primary prostate cancer, prostate bone metastasis, melanoma, and brain cancer – glioblastoma.   The company identified a new approach to treating ovarian cancer using its first cancer drug candidate that was funded by the National Cancer Institute of the National Institutes of Health, and is beginning the final research steps required by the FDA prior to submitting its application to conduct human clinical trials. 

The company's goal is to complete clinical drug development and achieve the same results as obtained in the laboratory.  If achieved this novel cancer treatment could change the current standard of care and improve patient survival and quality of life. And if demonstrated safe in early clinical trials, the company also intends to embark on clinical development for other cancer indications including breast and prostate cancers.

About Applied Integrin Sciences

Applied Integrin Sciences is a pre-clinical stage biopharmaceutical company committed to discover, develop, and commercialize novel protein drug therapies for cancer treatments that reduce solid tumor growth and progression and improve patient survival and quality of life.  The Company's Founding Scientists discovered, developed and patented a drug discovery platform to produce novel integrin modulating recombinant protein therapeutics that reduce tumor growth and progression in primary tumors, newly growing tumor-induced vasculature, and metastatic foci. The company is currently evaluating a novel treatment for ovarian cancer, an orphan indication recently funded by the NIH, as its first indication. For additional information about the company, please visit

About the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California

The Alfred E. Mann Institute for Biomedical Engineering was established at the University of Southern California in 1998.  Its mission is to help bridge the gap between biomedical innovation and the creation of commercially-successful medical products to improve and save lives.

About Three Two One Productions

Three Two One Productions is a company led by seasoned storytellers from film and television who create cutting edge business, bios, and legacy videos.

About When You Wish

When You Wish is a leading Internet "crowdfunding" company that combines payment processing and publishing tools to help entrepreneurs raise money online for their ideas or causes.

Source: Applied Integrin Sciences, Inc.

Public Relations.

(805) 715-4166

Media Contact: Public Relations, Applied Integrin Sciences, Inc., (805) 715-4166,

News distributed by PR Newswire iReach:

SOURCE Applied Integrin Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elsevier Launches New Open Access Journal: Applied and Translational Genomics
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
4. KannaLife Sciences, Inc. Signs Exclusive License Agreement with National Institutes of Health Office of Technology Transfer (NIH-OTT)
5. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
6. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
7. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
8. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
9. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
10. QPS Acquires JSW Life Sciences, Largest Independent Contract Research Organization in Austria
11. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
Post Your Comments:
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/27/2016)... ... ... recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
Breaking Medicine News(10 mins):